NOVN
Price:
$0.0941
Market Cap:
$2.64M
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; W...[Read more]
Industry
Biotechnology
IPO Date
2016-09-21
Stock Exchange
NASDAQ
Ticker
NOVN
According to Novan, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.40%. This represents a change of 480.17% compared to the average of 241.66% of the last 4 quarters.
The mean historical ROE of Novan, Inc. over the last ten years is -14.58%. The current 1.40% ROE has changed -9712.88% with respect to the historical average. Over the past ten years (40 quarters), NOVN's ROE was at its highest in in the June 2020 quarter at 21.85%. The ROE was at its lowest in in the March 2021 quarter at -1053.18%.
Average
-14.58%
Median
-78.71%
Minimum
-1013.20%
Maximum
1.67%
Discovering the peaks and valleys of Novan, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual ROE = 1.67%
Minimum Annual Increase = -969.49%
Minimum Annual ROE = -1013.20%
Year | ROE | Change |
---|---|---|
2022 | -424.78% | 169.84% |
2021 | -157.42% | -84.46% |
2020 | -1013.20% | -883.03% |
2019 | 129.39% | -153.07% |
2018 | -243.81% | -114.59% |
2017 | 1.67% | -969.49% |
2016 | -192.17% | -511.46% |
2015 | 46.70% | 21.18% |
2014 | 38.54% | Infinity% |
The current ROE of Novan, Inc. (NOVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-531.80%
5-year avg
-341.96%
10-year avg
-14.58%
Novan, Inc.’s ROE is greater than Tarsus Pharmaceuticals, Inc. (-63.99%), greater than LianBio (-38.06%), greater than Aldeyra Therapeutics, Inc. (-33.33%), greater than Travere Therapeutics, Inc. (-102.43%), greater than Eton Pharmaceuticals, Inc. (-43.62%), greater than Tonix Pharmaceuticals Holding Corp. (-158.27%), greater than Jaguar Health, Inc. (-354.93%), greater than Acasti Pharma Inc. (-18.84%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), greater than iBio, Inc. (-147.88%), greater than Aditxt, Inc. (-607.01%), greater than Palisade Bio, Inc. (-124.86%), less than Plus Therapeutics, Inc. (473.01%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Onconova Therapeutics, Inc. (-144.95%), greater than Adial Pharmaceuticals, Inc. (-291.06%), greater than Aeterna Zentaris Inc. (-84.15%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Trevi Therapeutics, Inc. (-49.92%), greater than SQZ Biotechnologies Company (-10.98%), greater than Protara Therapeutics, Inc. (-55.03%), greater than TRACON Pharmaceuticals, Inc. (-237.65%),
Company | ROE | Market cap |
---|---|---|
-63.99% | $1.16B | |
-38.06% | $34.47M | |
-33.33% | $364.25M | |
-102.43% | $839.88M | |
-43.62% | $118.59M | |
-158.27% | $3.14M | |
-354.93% | $10.26M | |
-18.84% | $24.44M | |
-55460.19% | $8.98M | |
-147.88% | $15.35M | |
-607.01% | $1.68M | |
-124.86% | $4.25M | |
473.01% | $8.31M | |
-243.91% | $1.43M | |
-112.11% | $3.06M | |
-144.95% | $20.90M | |
-291.06% | $6.40M | |
-84.15% | $17.51M | |
-143.74% | $17.85M | |
-49.92% | $214.15M | |
-10.98% | $12.83M | |
-55.03% | $38.27M | |
-237.65% | $194.57K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novan, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novan, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Novan, Inc.'s ROE?
How is the ROE calculated for Novan, Inc. (NOVN)?
What is the highest ROE for Novan, Inc. (NOVN)?
What is the 3-year average ROE for Novan, Inc. (NOVN)?
What is the 5-year average ROE for Novan, Inc. (NOVN)?
How does the current ROE for Novan, Inc. (NOVN) compare to its historical average?